Annual report [Section 13 and 15(d), not S-K Item 405]

Segment information

v3.25.1
Segment information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment information

13. Segment information

 

The Company operates and manages its business as one reportable and operating segment dedicated to the research and development Company’s novel orally administered antiviral influenza candidate. The measure of segment assets is reported on the balance sheet as total consolidated assets. In addition, the Company manages the business activities on a consolidated basis.

 

The Company’s CODM reviews financial information presented on a consolidated basis and decides how to allocate resources based on net income (loss).

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM (table in thousands):

 

Schedule of Segment Information 

             
    Year ended December 31,  
    2024     2023  
Revenue   $ -     $ -  
                 
Less:                
Research and development     10,785       13,492  
Salaries and personnel costs     2,900       2,840  
Insurance     286       358  
Stock-based compensation     643       801  
Operating expenses     3,264       1,068  
Other income     (374 )     (575 )
Net loss   $ (17,504 )   $ (17,984 )